Thu Jan 30 23:20:00 UTC 2025: ## FDA Approves First New Pain Reliever in Over Two Decades
**Washington, D.C.** – The U.S. Food and Drug Administration (FDA) announced Thursday the approval of Journavx (suztrigime), a new non-opioid pain reliever, marking the first such approval in over 20 years. This 50-milligram prescription pill, taken every 12 hours following a larger initial dose, offers a novel approach to pain management, addressing concerns surrounding opioid addiction.
Developed by Vertex Pharmaceuticals, suzetrigine works differently than opioids. Instead of dulling pain signals in the brain, it prevents pain-signaling nerves from firing altogether. This mechanism, inspired by research on a Pakistani family with a genetic inability to feel pain, minimizes the risk of addiction and euphoria associated with opioid painkillers.
Clinical trials involving nearly 600 participants demonstrated suzetrigine’s effectiveness in reducing pain following abdominal and foot surgeries. While not directly compared, its pain-reducing effects were comparable to Vicodin in these trials. However, results from a smaller study involving sciatica patients were less conclusive, suggesting the drug’s efficacy may vary depending on the type of pain.
Dr. Jacqueline Corrigan-Curay, acting director of the FDA’s Center for Drug Evaluation and Research, highlighted the agency’s commitment to providing safe and effective opioid alternatives. The approval of suzetrigine represents a significant step forward in addressing the national opioid crisis, which sees approximately half of the 80 million annual pain medication prescriptions written for opioids.
While lauded by pain management specialists as a welcome addition to treatment options, the cost of Journavx – $15.50 per 50-mg pill – and insurance coverage remain uncertainties. Experts emphasize that suzetrigine may not be suitable for all patients or pain types, and further research is ongoing to evaluate its long-term effectiveness in various chronic pain conditions.
First Piper 